

July 24, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015

Dear Sir/Madam,

Please take note that the Company received a letter from the Govt of National Capital Territory of Delhi, Health and Family Welfare Department on Friday July 21, 2017 after the close of market hours.

The Company in due compliance of such directive has temporarily suspended HLA Typing and DNA profiling tests at its Laboratory in E Block, Sector 18 Rohini, New Delhi 110018, with immediate effect for a period of three months and is simultaneously seeking appropriate legal advice.

While we believe the revenue impact of the above tests is not material, in the interest of transparency we are requesting you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary & Legal Head

